Warhound Launch: New Firm Targets Military Dog Shortage

Warhound emerged from stealth on Thursday with $200 million in new funding to develop genetically engineered dogs for the U.S. military and law enforcement. The venture is led by Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. Investors in the round include Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a firm supported by U.S. intelligence agencies. The funding values the company at $1.2 billion.

The company addresses a critical supply issue where more than 80 percent of working dogs used by the U.S. military are imported from Europe. Fewer than half of these imported animals are fit for service. Warhound plans to use genetic editing to create dogs with traits suited for demanding missions. The goal is to reduce reliance on foreign sources and improve the health and longevity of these service animals.

The dogs will perform tasks that are dangerous for humans or difficult for machines. These include bomb detection and specialized search operations. Lamm noted that many current working dogs fail training due to inherited issues like poor eyesight or hip dysplasia. The new dogs will be engineered to avoid these problems and enhance physical capabilities such as speed and agility.

Anduril will provide the hardware and software components for the program. This includes protective gear such as vests and goggles with data sensors. The equipment is designed to give handlers better situational awareness. Lamm described the approach as adding technology on top of the dog rather than changing its genetics. This combination aims to make the animals safer and more effective in the field.

Colossal Biosciences holds equity in Warhound and licenses its genetic technology to the new firm. Lamm and Luckey met a year ago at a conference and began collaborating on the project. The team is studying cell lines from high-performing breeds like the Belgian Malinois and German Shepherd. They will edit these genes to create a new type of working dog.

The first batch of dogs is scheduled to be cloned and incubated soon. Births are expected in early 2027, with service potentially beginning within two years. Viagen, another company owned by Colossal, will handle the cloning process. The firm has a high success rate in cloning, which it also uses for endangered species conservation.

Warhound has not yet set a price for the dogs but expects to sell to the Department of Defense, police forces, and other first responders. The company has briefed various government groups on its plans. The American Humane Society is guiding the certification of the training program. The Society stated that it looks forward to working with Warhound to ensure the animals are treated humanely.